Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

25.72
-0.1100-0.43%
Post-market: 25.720.00000.00%16:20 EDT
Volume:1.53M
Turnover:39.47M
Market Cap:2.53B
PE:-4.41
High:26.09
Open:25.75
Low:25.30
Close:25.83
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:94.49M
Volume Ratio:0.63
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-8.69
PE(LYR):-4.41

Loading ...

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Benzinga_recent_news
·
Mar 13

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Reuters
·
Mar 12

Ultragenyx Phase 3 Enh3ance study showed statistically significant results

TIPRANKS
·
Mar 12

Ultragenyx reports Phase 3 Enh3ance trial shows DTX301 cuts plasma ammonia AUC by 18% at Week 36

Reuters
·
Mar 12

Ultragenyx Announces Positive 36-Week Data From Phase 3 Study of Dtx301 Aav8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (Otc) Deficiency

THOMSON REUTERS
·
Mar 12

Ultragenyx Pharmaceutical Inc - Dtx301 Shows 18% Reduction in 24-Hour Plasma Ammonia at Week 36 Versus Placebo

THOMSON REUTERS
·
Mar 12

Ultragenyx Pharmaceutical Inc - Dtx301 Well Tolerated With Acceptable Safety Profile

THOMSON REUTERS
·
Mar 12

Ultragenyx Pharmaceutical Inc - Fewer Hyperammonemic Crises and No Deaths in Dtx301 Group Compared to Placebo

THOMSON REUTERS
·
Mar 12

Ultragenyx Pharmaceutical Inc - Secondary Endpoint Data on Treatment Burden Reduction Expected First Half 2027

THOMSON REUTERS
·
Mar 12

Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire
·
Mar 12

Ultragenyx price target lowered to $74 from $120 at JPMorgan

TIPRANKS
·
Mar 12

Ultragenyx faces securities class action over August 2023–December 2025 disclosures

Reuters
·
Mar 11

How Setrusumab Trial Setbacks and Securities Suits May Impact Ultragenyx Pharmaceutical (RARE) Investors

Simply Wall St.
·
Mar 10

Ultragenyx Faces Securities Class Action Over Setrusumab Trial Disclosures

Reuters
·
Mar 08

Samhi Hotels to Acquire 70% Stake in Luxury Hotel Aggregator RARE India

TIPRANKS
·
Mar 05

Rosen Law Firm Urges Ultragenyx Investors to Seek Counsel Ahead of April 6 Lead Plaintiff Deadline

Reuters
·
Mar 05

Levi & Korsinsky Files Securities Class Action Against Ultragenyx

Reuters
·
Mar 04

Ultragenyx Hit With Securities Class Action Lawsuit

Reuters
·
Mar 03

Class Action Lawsuit Targets Ultragenyx Pharmaceutical Inc. Investors

Reuters
·
Mar 02

Ultragenyx Investors File Securities Class Action Lawsuit

Reuters
·
Feb 26